More papers that ARE being presented at ASCO (group 4)


The following report gives core information on a fourth group of 15 papers that are being formally presented at ASCO. Again, we have highlighted the names of the authors and the titles of the papers that look to be of particular interest:

  • Nguyen et al. (“Postrandomization analysis assessing survival following radiation therapy [RT] with or without 6 months of androgen suppression therapy [AST] for localized prostate cancer [PCa]“) report that the combination of 6 months of androgen ablation with radiation therapy as first line treatment offers a survival benefit only to low risk patients.
  • Sinibaldi et al. (“A randomized double blind phase I-II study to determine the tolerability/efficacy of two different doses of lenalidomide [L], CC- 5013, in biochemically relapsed [BR] prostate cancer [PC] patients [pts] [M0] after local treatment [LT]”) will provide updated results of a preliminary trial of lenalidomide in treatment of patients who have biochemical failure after first-line treatment.
  • Poiesz et al. (“Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel [D] and prednisone [P] in men with docetaxel refractory prostate cancer”) and McVicar et al. (“An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel [D] and prednisone [P] in men with castrate-resistant prostate cancer [CRPC]”) will present two papers with Phase I/II data on AT-101 in treatment of CRPC.
  • Gillison et al. (“Docetaxel and imatinib every 21 days for castration resistant prostate cancer: a phase II trial”) will report Phase II data on the use of docetaxel + imatinib for treatment of patients with CRPC.
  • Luu et al. (“Comparability of health-related quality of life [HRQOL], treatment decision making, and treatment satisfaction after PSA recurrence among prostate cancer patients who receive hormone therapy [HT] versus observation [OBS]: results from the COMPARE registry“) report data on patient satisfaction with androgen deprivation therapy and observation (no therapy) for men who have biochemical progression.
  • Feyerabend et al. (“HLA-associated multipeptide vaccination in biochemically relapsed prostate cancer patients”) have shown that a multi-peptide immunotherapeutic “vaccine” can induce potentially significant clinical responses in some men with biochemical progression after first-line therapy.
  • Armstrong et al. (“Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate the identification of active chemotherapy regimens”) have defined three risk groups (good, intermediate, poor) for potential stratification of men with metastatic CRPC in future clinical trials.
  • Karakunnel et al. (“Cediranib [AZD2171] in docetaxel-resistant, castration-resistant prostate cancer [CRPC]”) will update early data on cediranib as a targeted treatment for CRPC.
  • Prins et al. (“C-reactive protein as adverse prognostic marker for men with castration-resistant prostate cancer [CRPC]: confirmatory results”) have confirmed that higher baseline CRP levels are associated with shorter survival in men with CRPC.
  • Pinthus et al. (“Two-years biochemical failure-free survival following high intensity focused ultrasound [HIFU] for localized prostate cancer: prospective single center study of 196 patients”) report data on 2-year biochemical recurrence-free survival after first-line HIFU using several different definitions of recurrence.
  • Heiden et al. (“PITX2 methylation and biochemical recurrence in postradical prostatectomy prostate cancer patients”) report that PITX2 methylation status may help to identify patients at risk for progression before and after first-line therapy.
  • Sonpavde et al. (“Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer [PCa] followed by radical prostatectomy [RP]”) provide data on the potential use of short-term, neoadjuvant bortezimib prior to radical prostatectomy in high-risk patients.
  • Sun et al. (“Differential survival after prostate cancer by race: role of NCI-designated comprehensive cancer centers”) have shown that (in the Los Angeles area) patients treated at NCI-designated CCCs have lower mortality compared with other facilities but that African Americans are less likely to go to NCI-dersignated CCCs for prostate cancer treatment.
  • Beardsley et al. (“A phase II study of patupilone in patients [pts] with metastatic castration-resistant prostate cancer [CRPC] who have progressed after docetaxel”) have reported data on a Phase II trial of a new epothilone in second-line chemotherapy of CRPC.
  • Cuppone et al. (“Short-term [ST] versus long-term [LT] hormone treatment [HT] in combination with radiotherapy [RT] for locally advanced prostate cancer [LAPC]: meta-analysis of randomized trials [RCTs]”) have shown that long-term androgen suppression may be more effective than short-term androgen suppression when given in combination with external beam radiotherapy.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: